Entry 26
Probiotic science page
Uses spore-based survival and protease production to improve protein absorption and reduce exercise-induced muscle damage, with RCT evidence.
Overview
Bacillus coagulans GBI-30, 6086 (trade name GanedenBC30, now marketed as BC30 by ADM/Kerry) is a probiotic strain that forms spores (tough survival shells). It produces lactic acid. Ganeden Biotech originally isolated it [1,6]. Phylogenomic analyses reclassified the strain to the genus Heyndrickxia. The clinical literature retains the Bacillus designation [1]. Unlike traditional lactobacilli, B. coagulans forms endospores that survive thermal processing and gastric transit. This allows incorporation into baked goods, beverages, and shelf-stable supplements [6]. Multiple human RCTs have evaluated GBI-30, 6086 for gastrointestinal function, immune support, and protein utilization [1,2,3,4].
Mechanism
B. coagulans GBI-30, 6086 produces endospores. These germinate in the small intestine upon exposure to bile salts and mild acidity. The resulting vegetative cells produce only lactic acid from sugar, yielding L(+)-lactic acid [1,6]. The strain secretes a bacteriocin-like inhibitory substance. This substance is active against Gram-positive and selected Gram-negative bacteria. Its spectrum and potency are modest compared to pharmaceutical antibiotics [6]. In the body, supplementation increases intestinal Bacteroides. It reduces Clostridium, Blautia, and Ruminococcus populations. This suggests modulation of the colonic microbiome composition [1] (RCT). B. coagulans also expresses beta-galactosidase. This contributes to improved lactose hydrolysis in the gut lumen [5] (animal). The spore’s thermal stability (surviving >100°C for limited durations) and gastric acid resistance permit survival through food processing and upper GI transit. This differentiates the strain from probiotics that do not form spores [6].
Health Benefits
A double-blind RCT enrolled 111 healthy Chinese adults with functional GI complaints. It showed that 1 × 10^9 CFU (colony-forming units, a live bacteria count) per day of BC30 for 4 weeks significantly increased stool frequency (P = 0.036). It improved fecal consistency (P < 0.001) and reduced constipation (P < 0.001) compared to placebo [1] (RCT). A double-blind RCT enrolled 200 Mexican schoolchildren. Those supplemented with GBI-30, 6088 (a closely related designation) showed reduced upper respiratory and gastrointestinal symptom duration. The study also showed modulation of immune-related proteins [2] (RCT). A double-blind RCT enrolled 60 healthy older adults (mean age ~70 years). It found that BC30 supplementation for 28 days increased Faecalibacterium prausnitzii populations. This is a butyrate-producing commensal associated with anti-inflammatory effects [4] (RCT). In 14 soldiers during intense military training, co-supplementation of GBI-30, 6086 with HMB reduced muscle damage markers. It also modulated cytokine response [3] (RCT). In rats, BC30 improved lactose digestion. It reduced breath hydrogen after a high-lactose challenge [5] (animal). A review concluded that GBI-30, 6086 improves protein absorption and utilization. This may support muscle recovery in athletes [6] (review). Evidence quality is moderate. Several trials had small sample sizes.
Biology
Bacillus coagulans (reclassified as Heyndrickxia coagulans [1]) is a Gram-positive rod that grows with or without oxygen and forms spores (tough survival shells). It measures approximately 0.5-1.0 × 2.0-5.0 µm [6]. The strain produces terminal to subterminal endospores. These confer resistance to heat (surviving baking temperatures), desiccation, and acidic environments [6]. Its metabolism produces only lactic acid from sugar, yielding L(+)-lactic acid from glucose. Unlike some Bacillus species, it does not produce gas from glucose [6]. B. coagulans is catalase-negative or weakly positive. It grows optimally at 35-50°C [6]. Natural isolation sources include soil, dairy products, and plant material. Whole-genome phylogenetic analysis prompted the reclassification to Heyndrickxia [unverified: original reclassification paper (Patel & Gupta, 2020) not found in PubMed]. The name Heyndrickxia coagulans appears in recent clinical literature [1].
Bibliography
Gang H, Wei J, McFarland LV, et al. (2025). Impact of Heyndrickxia (Bacillus) coagulans GBI-30, 6086 (BC30) probiotic on gastrointestinal function in healthy adults: a randomised controlled trial. Beneficial Microbes. 17(1):29-46. PMID: 40707016
Anaya-Loyola MA, Enciso-Moreno JA, López-Ramos JE, et al. (2019). Bacillus coagulans GBI-30, 6068 decreases upper respiratory and gastrointestinal tract symptoms in healthy Mexican scholar-aged children by modulating immune-related proteins. Food Research International. 125:108567. PMID: 31554075
Gepner Y, Hoffman JR, Shemesh E, et al. (2017). Combined effect of Bacillus coagulans GBI-30, 6086 and HMB supplementation on muscle integrity and cytokine response during intense military training. Journal of Applied Physiology. 123(1):11-18. PMID: 28408697
Nyangale EP, Farmer S, Cash HA, et al. (2015). Bacillus coagulans GBI-30, 6086 modulates Faecalibacterium prausnitzii in older men and women. Journal of Nutrition. 145(7):1446-1452. PMID: 25948780
Teichenné J, Catalán Ü, Mariné-Casadó R, et al. (2023). Bacillus coagulans GBI-30, 6086 (BC30) improves lactose digestion in rats exposed to a high-lactose meal. European Journal of Nutrition. 62(6):2649-2659. PMID: 37249602
Jäger R, Purpura M, Farmer S, et al. (2018). Probiotic Bacillus coagulans GBI-30, 6086 improves protein absorption and utilization. Probiotics and Antimicrobial Proteins. 10(4):611-615. PMID: 29196920
Available Products
GanedenBC30 (originally Ganeden Biotech, acquired by Kerry Group, now ADM) is sold as a spore-based probiotic ingredient in dietary supplements, functional foods, and beverages [1,6]. The strain is incorporated into products under the BC30 brand. Formats include capsules, powders, and baked or thermal-processed foods. Kerry Inc. (Quebec, Canada, Granada, Spain) supplies it as a finished ingredient [1]. Typical dosage in clinical studies ranges from 1 × 10^9 to 1.5 × 10^9 CFU per day [1,3].